More recently, Nemvaleukin Alfa, a reformulated IL-2 variant, was developed to retain the anti-tumor benefits of IL-2 while minimizing the cytokine-induced toxicity associated with earlier IL-2 therapies. Here, IL2 is linked to neoplasm.